Amylyx Pharmaceuticals Inc [AMLX] stock is trading at $5.76, up 5.88%. An important factor to consider is whether the stock is rising or falling in short-term value. The AMLX shares have gain 12.50% over the last week, with a monthly amount glided 24.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Mizuho upgraded its rating to Outperform on April 07, 2025, and kept the price target unchanged to $7. On November 18, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $11 on the stock. BofA Securities upgraded its rating to a Buy and increased its price target to $10 on October 23, 2024. Mizuho downgraded its rating to a Neutral and reduced its price target to $4 on March 18, 2024. Robert W. Baird downgraded its rating to Neutral for this stock on March 11, 2024, and downed its price target to $4. In a note dated March 11, 2024, Leerink Partners downgraded an Market Perform rating on this stock and revised its target price from $27 to $4.
Amylyx Pharmaceuticals Inc [AMLX] stock has fluctuated between $1.58 and $7.27 over the past year. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $5.76 at the most recent close of the market. An investor can expect a potential return of 73.61% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] reported sales of -1.27M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 7.76% with Operating Profit Margin at 163.17%, Pretax Profit Margin comes in at 172.56%, and Net Profit Margin reading is 172.06%. To continue investigating profitability, this company’s Return on Assets is posted at -1.0, Equity is -1.06 and Total Capital is -1.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Amylyx Pharmaceuticals Inc’s Current Ratio is 12.05. On the other hand, the Quick Ratio is 12.05, and the Cash Ratio is 3.33.
Transactions by insiders
Recent insider trading involved FRATES JAMES M, Chief Financial Officer, that happened on Mar 31 ’25 when 10896.0 shares were sold. Chief Medical Officer, Bedrosian Camille L completed a deal on Mar 31 ’25 to sell 12425.0 shares. Meanwhile, Chief Legal Officer Mazzariello Gina sold 9192.0 shares on Mar 31 ’25.
